X

Trial Profile

A Phase 1 Study Combining MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; MM-151 (Primary) ; Fluorouracil; Folinic acid
Indications Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Merrimack Pharmaceuticals

Most Recent Events

08 Jan 2017 According to a Merrimack Pharmaceuticals media release, company discontinued this study until conditions are appropriate to invest in this study.
08 Jan 2017 Status changed from recruiting to discontinued, as per a Merrimack Pharmaceuticals media release.
07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com